Helix BioPharma Corp., a clinical-stage oncology company dedicated to transforming the treatment of hard-to-treat cancers, has announced significant additions to its leadership team. Veronika Kandziora has been appointed as Chief Operating Officer (COO), and Jessica Kourniaktis, DPhil, as Director of Communications. These appointments are poised to bolster the company's strategic and operational capabilities as it advances its promising portfolio of oncology therapies.
Ms. Kandziora brings over 20 years of leadership experience in the biopharma, financial, and consulting sectors to her new role. Her extensive background includes serving as Corporate Secretary of Helix and as a strategic consultant, providing her with a deep understanding of the company's operations and goals. Her expertise in corporate strategy, transformation, and stakeholder engagement is expected to be invaluable as Helix enters a critical phase of its development. More about Helix BioPharma Corp. can be found at https://www.helixbiopharma.com/.
Dr. Kourniaktis, with her unique blend of life sciences expertise and communications strategy, is set to enhance Helix's ability to articulate its vision and engage with stakeholders effectively. Her academic background in the Humanities and her experience in the life sciences sector equip her with the skills to combine analytical depth with compelling storytelling, a critical asset for the company's communication efforts.
The CEO of Helix BioPharma, Thomas Mehrling, MD, PhD, highlighted the strategic importance of these appointments. He noted that Ms. Kandziora's organizational leadership and familiarity with the company, combined with Dr. Kourniaktis's strategic approach to communications, strengthen the leadership team at a pivotal time. These appointments underscore Helix's commitment to clarity, focus, and execution in its mission to deliver innovative treatments for hard-to-treat cancers.
The addition of Ms. Kandziora and Dr. Kourniaktis to the Helix leadership team reflects the company's strategic focus on strengthening its operational and communication frameworks. This move is indicative of Helix's dedication to advancing its clinical-stage oncology therapies and achieving its long-term goals in the fight against cancer.
